MNPR · Monopar Therapeutics Inc.

The thesis

Monopar Therapeutics' Wilson disease drug, ALXN1840, still has an open path to US approval, but the shares have kept falling without company news. The last close was $71.84 on 27 October 2026, 42.0% below the 52-week high of $123.84 and down 37.3% over three months. Completion of the rolling New Drug Application (NDA) and the Food and Drug Administration's (FDA) decision to accept it for review settle what comes next.

The narrative is fading: the shares closed at $96.47 on 18 September 2026, $73.10 on 14 October 2026 and $71.84 on 27 October 2026, and no Monopar press release has appeared since 19 August 2026. The 14-day relative strength index (RSI, a 0–100 momentum gauge) was 28.2 on 27 October 2026; readings under 30 are conventionally called oversold.

Since the 15 October 2026 note, searches of company news and analyst coverage found no NDA completion announcement and no new filing. On 12 August 2026 the company said it expected to finish the submission "within the next few months". Its earlier plan, in the 2025 year-end report, was a mid-2026 submission.

Bullish and bearish views on Monopar Therapeutics Inc.

The bull case on Monopar Therapeutics Inc. (MNPR), in brief: The regulatory process is under way. The bear case: The decline has continued without news.

Bull case

• The regulatory process is under way. Monopar announced on 22 July 2026 that the FDA authorized a rolling NDA and that the first completed sections were submitted. Completion starts the FDA's 60-day filing-decision clock.
• Cash covers the next 14 months. The Q2 2026 10-Q reports $134.3 million in cash, cash equivalents and investments at 30 June 2026, with funding guided through at least 31 December 2027.
• Analyst targets sit far above the price. Barclays raised its target to $145 on 11 September 2026 and keeps a Buy rating, per a MarketBeat-derived report. BTIG's target is $133 with a Buy rating (Benzinga, 12 August 2026). The consensus target was $121.36 on 29 September 2026, per Stock Observer.
• The drug holds a rare pediatric designation. The FDA granted Rare Pediatric Disease Designation to ALXN1840 on 30 June 2026. It keeps open a priority review voucher if approval comes while the FDA's voucher authority runs, currently through 30 September 2029.
• Scheduled data are close. Monopar announced on 19 August 2026 an oral presentation on 8 November 2026 and a poster on 5 November 2026 at the AASLD Liver Meeting in Denver.

Bear case

• The decline has continued without news. Closes fell from $96.47 on 18 September 2026 to $73.10 on 14 October 2026 and $71.84 on 27 October 2026 (adjusted daily closes). The earlier weekly level near $100 failed in September.
• Insiders sold into the decline. CEO Chandler Robinson sold 29,056 shares at $87.15 to $89.79 under a Rule 10b5-1 plan adopted 25 June 2026 (SEC Form 4 filed 24 September 2026). Two directors sold at $109 to $113 on 25 August 2026 and 26 August 2026.
• Completion has no date. Three months after the first submission, no completion release exists. The Q3 report, expected around 12 November 2026, is the next scheduled checkpoint.
• The pivotal result rests on a biomarker. The Phase 3 FoCus study met its primary endpoint on copper mobilization over 48 weeks, not a clinical outcome. The 10-Q warns the FDA may decline to accept or approve the application.
• Analyst ratings have split. Cantor Fitzgerald cut the shares to Neutral and raised its target to $119 on 13 August 2026 (Benzinga).

Price setup

The shares closed at $71.84 on 27 October 2026, 42.0% below the 52-week high of $123.84. The 200-day moving average stood at $82.32 and the 50-day at $109.77 on 29 September 2026 (Stock Observer). The price sits below both, and the 50-day average has been falling toward it.

The next round-number level below is $70, 2.6% under the last close. A close under $70 would extend a decline of roughly $52 from the high.

Monopar reports about 6.71 million shares outstanding, so moves in either direction can be large on modest volume. Crowding evidence is limited to the insider sales above and the 12 November 2026 (est.) earnings date. No equity offering has been filed.

Catalysts, next 30 days

• 5 November 2026 and 8 November 2026, AASLD Liver Meeting. A poster on molybdenum balance and an oral session on residual disease burden in treatment-experienced patients.
• ~12 November 2026 (est.), Q3 2026 results. Shows whether the submission is complete and whether the funding-through-2027 language holds.

Elapsed catalysts

• ~31 October 2026 (est.), NDA completion. The company has given no date beyond "the next few months" (12 August 2026). Completion starts the FDA's 60-day filing clock. (passed 6d ago)

What would change the view

The case breaks if the FDA refuses to file the application or asks for more data, since the pivotal endpoint was a biomarker. It also breaks if completion slips well past the "next few months" language, or if Monopar sells equity below recent trading levels. A daily close below $70 would extend the decline and end the case.

The case improves if the company announces a completed NDA and the shares reclaim the 200-day moving average, last reported at $82.32 on 29 September 2026. Further Form 4 sales or new Rule 10b5-1 plans would weaken it.

What it trades with

Monopar trades on its own regulatory timeline rather than with a sector basket. The shares fell about 41% from the 18 September 2026 close to the 27 October 2026 close with no company news, which points to stock-specific selling. The ALXN1840 programme was licensed from AstraZeneca/Alexion on 24 October 2024, and the MNPR-101 radiopharma program is early-stage with no dated readout.